July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Long-term outcomes in ranibizumab-treated East Asian patients with myopic choroidal neovascularization in the 36-month post-RADIANCE study period
Author Affiliations & Notes
  • Mark Wieland
    Northern California Retina Vitreous Associates, Mountain View, California, United States
  • Bann-mo Day
    Genentech, Inc., South San Francisco, California, United States
  • Tatiana Eccoffier
    Genentech, Inc., South San Francisco, California, United States
  • Shamika Gune
    Genentech, Inc., South San Francisco, California, United States
  • Zdenka Haskova
    Genentech, Inc., South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Mark Wieland, Alcon (C), Allergan (C), Compact Imaging (C), Genentech Inc. (C), Novartis (C), Roche (C), Zeiss (C); Bann-mo Day, Genentech, Inc. (E), Genentech, Inc. (I); Tatiana Eccoffier, Genentech, Inc. (E), Genentech, Inc. (I); Shamika Gune, Genentech, Inc. (E), Genentech, Inc. (I); Zdenka Haskova, Genentech, Inc. (E), Genentech, Inc. (I)
  • Footnotes
    Support  Genentech, Inc., South San Francisco, CA, provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 784. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mark Wieland, Bann-mo Day, Tatiana Eccoffier, Shamika Gune, Zdenka Haskova; Long-term outcomes in ranibizumab-treated East Asian patients with myopic choroidal neovascularization in the 36-month post-RADIANCE study period. Invest. Ophthalmol. Vis. Sci. 2018;59(9):784.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Patients of Asian descent are at a higher risk of developing myopic choroidal neovascularization (mCNV), a vision-threatening complication of pathological myopia. This post-RADIANCE retrospective cohort study assessed the long-term efficacy, safety, and treatment burden of intravitreal 0.5 mg ranibizumab (RBZ) in East Asian patients with mCNV over the 36 months following the 12-month, phase 3 RADIANCE trial (NCT01217944).

Methods : The RADIANCE trial compared verteporfin photodynamic therapy vs 2 treatment regimens of 0.5 mg RBZ in patients with mCNV: guided by either disease activity or visual stability criteria. The post-RADIANCE retrospective analysis examined the safety and efficacy of RBZ in patients of East Asian descent who completed RADIANCE and attended at least 1 follow-up visit in the 36 months (M13–48) following the trial. The primary outcome measure was mean BCVA change from baseline to each visit over the 36-month follow-up study. Secondary outcome measures included recurrence of mCNV in the study eye and ocular adverse events (AEs) during the 36-month follow-up.

Results : In this retrospective analysis of post-RANDIANCE patients (N=41; 14.8% of RADIANCE), mean BCVA gains from RADIANCE baseline were 14.3 ± 11.4 ETDRS letters (n=40; P < 0.0001) at M12, and were maintained through the follow-up period to 16.3 ± 18.7 (n=16, P = 0.0034) at M48. From M13–48, only 7 patients (17.1%) required additional anti-VEGF injections (5.0 ± 5.9; group A), while 34 (82.9%) did not (group B). The mean central retinal thickness (CRT; µm) in groups A and B in the post-RADIANCE study period was comparable (379.0 ± 72.8 and 382.1 ± 108.6). Of the 41 patients in the follow-up study, 4 patients had recurrences (2 reactivations of previously regressed mCNV and 2 newly formed). Of these, 2 (4.9%) experienced a single episode, 2 (4.9%) had a second recurrence. No patients experienced a third recurrence during the follow-up study. Ocular AEs were reported in 5 (12.2%) patients, however, none were considered serious or related to RBZ treatment.

Conclusions : The significant vision gains achieved in East Asian mCNV patients with RBZ treatment at M12 were maintained over an additional 36-month period with only a minority of patients requiring additional injections. Few patients experienced recurrence of mCNV. No new safety findings were reported.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×